Abeona Therapeutics Inc. (Nasdaq: ABEO), a biopharmaceutical company co-headquartered in Cleveland and New York, has received the go-ahead from the U.S. Food and Drug Administration to move forward with a key clinical trial.
The company said in a news release that the FDA has removed a clinical hold and cleared Abeona to proceed with its VITAL study, a Phase 3 clinical trial evaluating the EB-101 cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, or RDEB, a rare connective tissue disorder without an approved therapy.
Click here to read the complete article.
Story excerpt provided by Crain’s Cleveland Business.
Written by Scott Suttell.
Originally published December 10, 2019.